Abstract: The present invention concerns a process for preparing a compound having the Formula A; or a pharmaceutically acceptable salt or derivative thereof, or for preparing a substituted urea compound of Formula IIa, or a pharmaceutically acceptable salt or ester thereof, the process comprising the reaction of an imidazolyl intermediate of Formula IIa? with a carbamoyl halide of the formula: R1R2NC(?O)Hal, wherein Hal represents Cl, F, I or Br, wherein the intermediate of Formula IIa? is prepared by oxidation of the derivative of R5 and R6, R6-C(?O)CH2R5 to form a glyoxal intermediate R6-C(?O)(C?O)R5, which is subjected to treatment with ammonium hydroxide and an aldehyde R8CHO to provide the intermediate of Formula IIa? and wherein the compound substituents are as defined herein.

Abstract: The present invention concerns a process for preparing a compound having the Formula A; or a pharmaceutically acceptable salt or derivative thereof, or for preparing a substituted urea compound of Formula IIa, or a pharmaceutically acceptable salt or ester thereof, the process comprising the reaction of an imidazolyl intermediate of Formula IIa? with a carbamoyl halide of the formula: R1R2NC(?O)Hal, wherein Hal represents Cl, F, I or Br, wherein the intermediate of Formula IIa? is prepared by oxidation of the derivative of R5 and R6, R6-C(?O)CH2R5 to form a glyoxal intermediate R6-C(?O)(C?O)R5, which is subjected to treatment with ammonium hydroxide and an aldehyde R8CHO to provide the intermediate of Formula IIa? and wherein the compound substituents are as defined herein.

Abstract: There is disclosed a methylated intermediate which may be demethylated to provide an inhibitor of catechol-O-methyltransferase useful in the treatment of Parkinson's disease. Also disclosed are methods of making and using said intermediate.

Abstract: The present invention concerns a process for preparing a compound having the Formula A: or a pharmaceutically acceptable salt or derivative thereof, or for preparing a substituted urea compound of Formula IIa, or a pharmaceutically acceptable salt or ester thereof, the process comprising the reaction of an imidazolyl intermediate of Formula IIa?, with a carbamoyl halide of the formula: R1R2NC(?O)Hal, wherein Hal represents Cl, F, I or Br, wherein the intermediate of Formula IIa? is prepared by oxidation of the derivative of R5 and R6, R6-C(?O)CH2R5 to form a glyoxal intermediate R6-C(?O)(C?O)R5, which is subjected to treatment with ammonium hydroxide and an aldehyde R8CHO to provide the intermediate of Formula IIa?, and wherein the compound substituents are as defined herein.

Abstract: There is disclosed a methylated intermediate which may be demethylated to provide an inhibitor of catechol-O-methyltransferase useful in the treatment of Parkinson's disease. Also disclosed are methods of making and using said intermediate.

Abstract: There is disclosed a methylated intermediate which may be demethylated to provide an inhibitor of catechol-O-methyltransferase useful in the treatment of Parkinson's disease. Also disclosed are methods of making and using said intermediate.

Abstract: A process for preparing a substituted urea compound of Formula II or Formula I, or a pharmaceutically acceptable salt or ester thereof, Formula II, Formula I the process comprising the reaction of an intermediate of Formula II? or Formula 1?, Formula II?, Formula I? with a carbamoyl halide of the formula: R1R2NC(=0)Hal, in a solvent consisting essentially of pyridine, wherein Hal represents Cl, F, I or Br, and wherein ring A, and R1, R2, R5, V, W, X, Y and Z are as defined herein.

Abstract: This invention relates to novel polymorphs of (HO)2NO2(C6H)—(C2N2O)—(C5N)(CH3)2Cl2O, to processes for their preparation, and to pharmaceutical compositions containing said novel polymorphs as active pharmaceutical ingredient.

Abstract: There is disclosed a methylated intermediate which may be demethylated to provide an inhibitor of catechol-O-methyltransferase useful in the treatment of Parkinson's disease. Also disclosed are methods of making and using said intermediate.

Abstract: This invention relates to novel polymorphs of (HO)2NO2(C6H)—(C2N2O)—(C5N)(CH3)2Cl2O, to processes for their preparation, and to pharmaceutical compositions containing said novel polymorphs as active pharmaceutical ingredient.

Abstract: The invention relates to benzopyran compounds of formula (I) possessing pharmacological activity, as well as to pharmaceutical compositions containing the compounds of formula (I) and processes for the preparation thereof.

Abstract: A process is disclosed for the preparation of (.+-.)-6-cyano-3,4-dihydro-2,2-dimethyl-trans-4-(2-oxo-1-pyrrol idino)-2H-1-benzopyran-3-ol of the Formula (VI) ##STR1## from 4-cyanophenol of the Formula (I) ##STR2## which comprises reacting 4-cyanophenol of the Formula (I) with isoprene, followed with bromination and dehydrobromination steps with formation of intermediates to react with 2-pyrrolidone resulting in obtaining the compound of the Formula (VI).

Abstract: A process is disclosed for the preparation of (.+-.)-6-cyano-3,4-dihydro-2,2-dimethyl-trans-4-(2-oxo-1-pyrrol idino)-2H-1-benzopyran-3-ol of the Formula (VI) ##STR1## from 4-cyanophenol of the Formula (I) ##STR2## which comprises reacting 4-cyanophenol of the Formula (I) with isoprene, followed with bromination and dehydrobromination steps with formation of intermediates to react with 2-pyrrolidone resulting in obtaining the compound of the Formula (VI).